Tag Archive for: 177Lu-PSMA-617

177Lu-M3-12: a Novel PSMA-Targeted Radioligand Shows Higher Tumour Uptake Than 177Lu-PSMA-617 in Preclinical Study

A new preclinical study published in EJNMMI Research reports promising results for 177Lu-M3-12, an experimental PSMA-targeted radioligand designed to improve tumour targeting and potentially reduce radiation exposure to healthy tissues in prostate cancer. The treatment uses lutetium-177, the same radioactive isotope employed in 177Lu-PSMA-617 (Pluvicto), but incorporates a different molecular structure featuring a hydrophilic linker. […]

ATM-Altered Prostate Cancer May Be Especially Sensitive to Lu-177-PSMA

A new study suggests that ATM alterations could identify a subgroup of metastatic castration-resistant prostate cancer particularly likely to benefit from 177Lu-PSMA-617 (Pluvicto). The retrospective analysis included 205 men with mCRPC treated with Lu-177-PSMA-617 between 2022 and 2026, all of whom had next-generation DNA sequencing available. ATM alterations were present in 12.7% of patients and […]

Tracking Response and Resistance to Lu-177 Plus Immunotherapy

A new analysis of the PRINCE clinical trial suggests that combining blood-based ctDNA testing with PSMA PET could help identify which men with metastatic castration-resistant prostate cancer (mCRPC) are most likely to respond to Lu-177 PSMA plus immunotherapy. PRINCE was a multicentre Phase 1/2 trial involving 37 men with mCRPC. Patients received up to six […]

CEA Emerges as a Potential Prognostic Marker for Lu-177 PSMA Therapy

A simple blood test normally associated with colorectal cancer could provide additional information about how men with metastatic castration-resistant prostate cancer fare after 177Lu-PSMA-617 therapy. A new prospective study of 142 patients found that elevated carcinoembryonic antigen (CEA) before treatment was independently associated with shorter progression-free and overall survival. The finding does not mean that […]

UPDATE: Phase 3 Pivotal Trial for 177Lu-NYM032

A PSMA-targeted radioligand built on a compound called NYM032 is heading into the pivotal phase 3 trial that will decide whether its early data hold up. The molecule can be labeled with gallium-68 for PET imaging or lutetium-177 for therapy, giving a matched diagnose-and-treat pair. In mouse tumor models, escalating the dose from 18.5 to […]

Pluvicto Moves Into First-Line Metastatic Prostate Cancer, Marking Shift Toward Earlier Radioligand Therapy

A new regulatory approval is reshaping the treatment landscape for metastatic hormone-sensitive prostate cancer (mHSPC), bringing radioligand therapy into much earlier stages of disease. Pluvicto (lutetium Lu-177 vipivotide tetraxetan aka 177Lu-PSMA-617), a therapy targeting prostate-specific membrane antigen (PSMA), can now be used in combination with standard androgen deprivation therapy and androgen receptor pathway inhibitors in […]

Phase 2 Trial for Xaluritamig in Patients With mCRPC and Suboptimal Response to Pluvicto

Thomas Jefferson University is running a phase 2 study of xaluritamig, also known as AMG 509, in adults with metastatic castration-resistant prostate cancer whose disease has shown a suboptimal response to Lu-177 vipivotide tetraxetan (aka 177Lu-PSMA 617) the radioligand therapy better known as Pluvicto. The trial reflects a very specific and clinically important question: what […]

Radioligand Therapy Plus CAR‑T: A New Strategy to Reprogram the Prostate Cancer Microenvironment

A new preclinical study shows that radioligand therapy (RLT) can directly enhance CAR‑T cell efficacy in metastatic castration-resistant prostate cancer (mCRPC), addressing two major barriers: antigen heterogeneity and an immunosuppressive tumor microenvironment (TME). Researchers combined 177Lu‑PSMA‑617 (Pluvicto) with PSCA-targeted CAR‑T cells in sequence (RLT → cyclophosphamide → CAR‑T). Compared to either treatment alone, the combination […]

Phase 1 Trial: 177Lu-PSMA-617 Plus Darolutamide in High-Risk Localized Prostate Cancer

A new trial phase 1 trial is investigating the combination of 177Lu-PSMA-617 (Pluvicto) with darolutamide in high-risk localized prostate cancer. Both agents are already established in prostate cancer care, but using them together before surgery is a novel way to intensify treatment in patients whose disease is still potentially curable. Its main idea is simple: […]

Phase 1 Trial for a New PSMA Radioligand 177Lu‑PSMA‑VG01

177Lu‑PSMA‑VG01 is a next‑generation, small‑molecule PSMA‑targeting radiopharmaceutical designed to refine what 177Lu‑PSMA‑617 (Pluvicto) has already achieved. It uses a high‑affinity ligand to deliver the beta‑emitter lutetium‑177 directly to PSMA‑expressing tumor cells, aiming for greater tumor dosing with less exposure of healthy tissue. A new phase 1 trial is testing its dosimetry and side effects on […]